<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03451448</url>
  </required_header>
  <id_info>
    <org_study_id>17/SS/0151</org_study_id>
    <nct_id>NCT03451448</nct_id>
  </id_info>
  <brief_title>PET MRI in Coronary Artery Disease</brief_title>
  <official_title>Combined Magnetic Resonance Coronary Angiography and Positron Emission Tomography in Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the use of position emission tomography/magnetic resonance imaging
      (PET/MRI) using ultra-small-superparamagnetic particles of iron oxide (USPIO) as a contrast
      agent in patients with coronary artery disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Positron emission tomography/magnetic resonance imaging (PET/MRI) has the potential to
      provide detailed information on coronary artery anatomy, the presence of coronary artery
      stenosis, the composition of atherosclerotic plaque using MRI tissue characterisation and
      information about the underlying biological processes using targeted PET tracers.
      Ultra-small-superparamagnetic particles of iron oxide (USPIO) have a long blood pool
      half-life so are an ideal contrast agent for PET/MRI imaging.

      This study will assess the use of PET/MRI with USPIO in patients with stable coronary artery
      disease and recent acute myocardial infarction.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PET/MRI findings</measure>
    <time_frame>Immediately after PET/MRI scan</time_frame>
    <description>The primary endpoint will be the difference in MRI and PET characteristics of atherosclerotic plaques in patients with and without recent acute coronary syndromes.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <description>Healthy volunteers to undergo MRI using USPIO contrast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stable coronary artery disease</arm_group_label>
    <description>Patients with coronary artery disease without recent (3 months) acute coronary syndrome or revascularisation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recent acute coronary syndrome</arm_group_label>
    <description>Patients with recent (3 months) type 1 myocardial infarction</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET/MRI</intervention_name>
    <description>PET/MRI with USPIO contrast</description>
    <arm_group_label>Stable coronary artery disease</arm_group_label>
    <arm_group_label>Recent acute coronary syndrome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>MRI with USPIO contrast</description>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy volunteers to undergo MRI.

        Patients with stable coronary artery disease or recent acute myocardial infarction to
        undergo PET/MRI
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers to undergo MRI imaging will be over the age of 18 years and able to
             provide informed consent.

          -  Patients with coronary artery disease to undergo PET/MRI will have multi-vessel
             disease (≥2 vessel coronary artery disease with ≥ 50% cross-sectional luminal
             stenosis).

          -  able to provide informed consent

          -  over the age of 40 years

        Exclusion Criteria:

          -  inability or unwillingness to undergo magnetic resonance imaging or positron emission
             tomography

          -  renal failure (Serum creatinine &gt;200 umol/L or estimated glomerular filtration rate
             &lt;30 mL/min

          -  hepatic failure

          -  pregnancy

          -  inability to provide informed consent

          -  contraindications to undergoing MRI scanning

          -  contraindications to contrast agents not included above including evidence of iron
             overload, known allergy to constituents of the contrast agents, and anaemia not caused
             by iron deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Williams</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Williams</last_name>
    <phone>01312421000</phone>
    <email>michelle.williams@ed.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Williams, MBChB</last_name>
      <phone>01312426364</phone>
      <email>michelle.williams@ed.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Michelle Williams, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2018</study_first_submitted>
  <study_first_submitted_qc>February 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2018</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PET/MRI</keyword>
  <keyword>ultra-small-superparamagnetic particles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

